Dr. Butler is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2500 N State St
Jackson, MS 39216Phone+1 601-984-1000Fax+1 601-984-6439
Summary
- Javed Butler, MD, MPH, MBA, is the President of the Baylor Scott and White Research Institute, and Senior Vice President and Maxwell A. and Gayle H. Clampitt Endowed Chair at the Baylor Scott and White Health in Dallas, TX. He is also the Distinguished Professor of Medicine at University of Mississippi in Jackson, MS. Prior to joining Baylor Scott and White Health, he served as the Patrick H. Lehan Chair in Cardiovascular Research, and Professor and Chairman of the Department of Medicine at the University of Mississippi, where he was also Professor of Physiology. Prior to joining the University of Mississippi, he was Charles A. Gargano Professor and Director of the Division of Cardiovascular Medicine and Co-Director of the Heart Institute at Stony Brook University, New York. He had served as the director for heart failure research at Emory University and director of the heart and heart-lung transplant programs at Vanderbilt University prior to that.
He received his medical degree from the Aga Khan University and then completed residency training at Yale University, cardiology fellowship and advanced heart failure and transplant fellowships at Vanderbilt University, and cardiac imaging fellowship at the Massachusetts General Hospital at the Harvard Medical School. He has completed Master of Public Health degree from Harvard University and a Master in Business Administration from the Emory University.
Dr. Butler is board certified in cardiovascular medicine and advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure. He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America. He is the recipient of the Simon Dack Award by the American College of Cardiology as well as the Time, Feeling, and Focus Award by the American Heart Association.
Education & Training
- Vanderbilt University Medical CenterFellowship, Cardiovascular Disease, 1995 - 1998
- Yale-New Haven Medical CenterResidency, Internal Medicine, 1991 - 1994
- Aga Khan Medical CollegeClass of 1990
Certifications & Licensure
- GA State Medical License 2006 - 2025
- MS State Medical License 2018 - 2025
- NY State Medical License 2014 - 2025
- TN State Medical License 1999 - 2007
- CT State Medical License 1994 - 1999
- American Board of Internal Medicine Advanced Heart Failure and Transplant Cardiology
- American Board of Internal Medicine Cardiovascular Disease
Awards, Honors, & Recognition
- Atlanta Magazine: Top Doctors Castle Connolly, 2009-2014
- Super Doctor SuperDoctors.com
- Fellow (FACC) American College of Cardiology
Clinical Trials
- Heart Failure Study: The Atlanta Cardiomyopathy Consortium Start of enrollment: 2007 Nov 01
- Dopamine in Acute Decompensated Heart Failure II Start of enrollment: 2009 Jul 01
- Cost Effectiveness and Quality of Life in Heart Failure Patients With Diabetes Start of enrollment: 2009 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 200 citationsCancer Therapy–Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and ImagingMichelle W. Bloom, Carine E. Hamo, Daniela Cardinale, Bonnie Ky, Anju Nohria
Circulation. Heart Failure. 2016-01-01 - 195 citations2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure: A Report of the America...Steven M. Hollenberg, Lynne W. Stevenson, Tariq Ahmad, Vaibhav J. Amin, Biykem Bozkurt
Journal of the American College of Cardiology. 2019-10-15 - 50 citationsEffects of Canagliflozin on Amino-Terminal Pro-B-Type Natriuretic Peptide: Implications for Cardiovascular Risk Reduction.James L. Januzzi, Jialin Xu, Jingwei Li, Wayne Shaw, Richard Oh
Journal of the American College of Cardiology. 2020-11-03
Journal Articles
- Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease Among US Adults with DiabetesMichael C Honigberg, Ravi B Patel, Javed Butler, Darren K Mcguire, JAMA Cardiology
- Effect of a Self-Care Intervention on 90-Day Outcomes in Patients with Acute Heart Failure Discharged from the Emergency DepartmentPhillip D Levy, Deborah J Diercks, Gregory J Fermann, Brian Hiestand, Joann Lindenfeld, Jennifer Martindale, Javed Butler, JAMA Cardiology
- Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients with Heart Failure with Reduced Ejection Fraction in US Clinical PracticeMuthiah Vaduganathan, Javed Butler, Paul A Heidenreich, Michelle M Kittleson, Anjali Tiku Owens, Pamela N Peterson, Clyde W Yancy, Gregg C Fonarow, JAMA Cardiology
- Join now to see all
Lectures
- Heart Failure Prevention for AllHeart Failure Society of America, Bloomington, Minnesota - 9/27/2012
- Guideline Directed Management of a NYHA Class III Patient: How to Titrate What to Avoid Tools for Success and Practical Pearls2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
- Selecting A First-Choice Therapy For Systolic HF: The Growing Body of Evidence2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
Authored Content
- Trends in HF Hospitalizations Among Young Adults in the United States from 2004 to 2018May 2022
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureAugust 2020
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureAugust 2020
- Heart Failure Epidemiology in Patients with Diabetes Mellitus Without Coronary Heart DiseaseNovember 2018
- Patient and Practice Characteristics Associated with Sacubitril/Valsartan Use in the United StatesSeptember 2018
- Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients with Type 2 DiabetesMarch 2018
- 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure with Reduced Ejection Fraction A Report of the American College of Cardiology Task Force on Expert Consensus Decision PathwaysJanuary 2018
- 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure with Reduced Ejection Fraction A Report of the American College of Cardiology Task Force on Expert Consensus Decision PathwaysJanuary 2018
- 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure TreatmentDecember 2017
- 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure with Reduced Ejection FractionDecember 2017
- Join now to see all
Press Mentions
- URMC to Lead $27M Heart Failure Medication StudyAugust 13th, 2024
- Effect of Dapagliflozin on Health Status in Patients with Preserved or Mildly Reduced Ejection FractionDecember 14th, 2022
- Adding Salt to Foods and Risk of Cardiovascular DiseaseDecember 1st, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: